PRMT5 and hepatocellular carcinoma: HCC patients undergoing radiotherapy exhibit aberrant PRMT5 ASEs, typified by exon 3 and a portion of exon 4 skipping, resulting in the truncated PRMT5-ISO5.387 SRSF3 and HNRNPH1 foster the selection of an alternative 3’ss on exon 4 over a 3’ ss on intron 2 by competitively binding with PRMT5 pre-mRNA, thereby antagonistically regulating PRMT5 ASE.